Radioiodine (131 I, RAI) has traditionally been used in thyroid cancer treatment but its benefit should be balanced against possible risks. Among them, salivary gland dysfunction has often been discussed, although the reported data have been inconsistent. The aim of our prospective study was to evaluate salivary gland function in 31 thyroidectomised patients (6 men, 25 women; median age 52 yr) before and 4-6 months after RAI remnant ablation (RRA), using activity of 3.7 GBq 131 I-NaI. Salivary gland uptake and excretion fractions were quantitatively assessed with 99m Tc - pertechnetate salivary gland scintigraphy. Pre- and post-treatment values were compared using Wilcoxon signed rank test. No statistically significant difference in the pre- and post-treatment values was observed in parotid or submandibular glands uptake, or in the parotid or submandibular excretion fractions. The calculated power for minimum relevant difference of 25% with the sample size of 31 ranged between 86% and 96% for the individual variables, making our negative results reasonably reliable. The results suggest that RRA with the most commonly used activity of 3.7 GBq has no important impact on salivary gland function. Therefore, the concerns about putative salivary gland functional deterioration following RRA are probably unjustified.

4th Department of Internal Medicine University Hospital Hradec Králové Hradec Králové Czech Republic

Academic Department of Internal Medicine Faculty of Medicine in Hradec Králové Charles University Hradec Králové Czech Republic

Nuclear Medicine Department University Hospital Hradec Králové Hradec Králové Czech Republic

Zobrazit více v PubMed

Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006; 295: 2164–2167. PubMed

Lukas J, Drabek J, Lukas D, Dusek L, Gatek J. The epidemiology of thyroid cancer in the Czech Republic in comparison with other countries. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013; 157: 266–275. PubMed

Mazzaferri EL, Jhiang SM. Long‐term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418–428. PubMed

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26: 1–133. PubMed PMC

Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid 2000; 13: 265–271. PubMed

Tavares C, Coelho MJ, Eloy C, Melo M, da Rocha AG, Pestana A, Batista R, Ferreira LB, Rios E, Selmi‐Ruby S, Cavadas B, Pereira L, Sobrinho Simões M, Soares P. NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features. Endocr Connect 2018; 7: 78–90. PubMed PMC

Dohán O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, Ginter CS, Carrasco N. The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 2003; 24: 48–77. PubMed

Pink R, Simek J, Vondrakova J, Faber E, Michl P, Pazdera J, Indrak K. Saliva as a diagnostic medium. Biomed Pap 2009; 153: 103–110. PubMed

Twetman S. Prevention of dental caries as a non‐communicable disease. Eur J Oral Sci 2018; 126(Suppl): 19S–25S. PubMed

Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM. Intermediate and long‐term side effects of high‐dose radioiodine therapy for thyroid carcinoma. J Nucl Med 1998; 39: 1551–1554. PubMed

Walter MA, Turtschi CP, Schindler C, Minnig P, Müller‐Brand J, Müller B. The dental safety profile of high‐dose radioiodine therapy for thyroid cancer: long‐term results of a longitudinal cohort study. J Nucl Med 2007; 48: 1620–1625. PubMed

Grewal RK, Larson SM, Pentlow CE, Pentlow KS, Gonen M, Qualey R, Natbony L, Tuttle RM. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med 2009; 50: 1605–1610. PubMed

Hollingsworth B, Senter L, Zhang X, Brock GN, Jarjour W, Nagy R, Brock P, Coombes KR, Kloos RT, Ringel MD, Sipos J, Lattimer I, Carrau R, Jhiang SM. Risk factors of (131)I‐induced salivary gland damage in thyroid cancer patients. J Clin Endocrinol Metab 2016; 101: 4085–4093. PubMed PMC

Blumhardt R, Wolin EA, Phillips WT, Salman UA, Walker RC, Stack BC Jr, Metter D. Current controversies in the initial post‐surgical radioactive iodine therapy for thyroid cancer: a narrative review. Endocr Relat Cancer 2014; 21: R473–484. PubMed

Jentzen W, Hobbs RF, Stahl A, Knust J, Sgouros G, Bockisch A. Pre‐therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010; 37: 884–895. PubMed PMC

Klutmann S, Bohuslavizki KH, Kröger S, Bleckmann C, Brenner W, Mester J, Clausen M. Quantitative salivary gland scintigraphy. J Nucl Med Technol 1999; 27: 20–26. PubMed

Klein Hesselink EN, Brouwers AH, de Jong JR, van der Horst‐Schrivers AN, Coppes RP, Lefrandt JD, Jager PL, Vissink A, Links TP. Effects of radioiodine treatment on salivary gland function in patients with differentiated thyroidcarcinoma: a prospective study. J Nucl Med 2016; 57: 1685–1691. PubMed

Fogelman I, Clarke SEM, Cook G, Gnanasegaran G. An atlas of clinical nuclear medicine. Boca Raton, FL: CRC Press, 2014; 1245–1256.

Helman J, Turner RJ, Fox PC, Baum BJ. 99mTc‐pertechnetate uptake in parotid acinar cells by the Na+/K+/Cl‐ co‐transport system. J Clin Invest 1987; 79: 1310–1313. PubMed PMC

Jeong SY, Kim HW, Lee SW, Ahn BC, Lee J. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre‐ and post‐ablation scintigraphies and their relation to xerostomia symptoms. Thyroid 2013; 23: 609–616. PubMed PMC

Wu JQ, Feng HJ, Ouyang W, Sun YG, Chen P, Wang J, Xian JL, Huang LH. Systematic evaluation of salivary gland damage following I‐131 therapy in differentiated thyroid cancer patients by quantitative scintigraphy and clinical follow‐up. Nucl Med Commun 2015; 36: 819–826. PubMed

Maruoka Y, Baba S, Isoda T, Kitamura Y, Abe K, Sasaki M, Honda H. A functional scoring system based on salivary gland scintigraphy for evaluating salivary gland dysfunction secondary to (131)I therapy in patients with differentiated thyroid carcinoma. J Clin Diagn Res 2017; 11: TC23–TC28. PubMed PMC

Jo KS, An YS, Lee SJ, Soh EY, Lee J, Chung YS. Significance of salivary gland radioiodine retention on post‐ablation (131)I scintigraphy as a predictor of salivary gland dysfunction in patients with differentiated thyroid carcinoma. Nucl Med Mol Imaging 2014; 48: 203–211. PubMed PMC

Upadhyaya A, Meng Z, Wang P, Zhang G, Jia Q, Tan J, Li X, Hu T, Liu N, Zhou P, Wang S, Liu X, Wang H, Zhang C, Zhao F, Yan Z. Effects of first radioiodine ablation on functions of salivary glands in patients with differentiated thyroid cancer. Medicine (Baltimore) 2017; 96: e7164. PubMed PMC

Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, Bardet S, Leenhardt L, Bastie D, Schvartz C, Vera P, Morel O, Benisvy D, Bournaud C, Bonichon F, Dejax C, Toubert ME, Leboulleux S, Ricard M, Benhamou E. Tumeurs de la Thyroïde Refractaires Network for the Essai Stimulation Ablation Equivalence Trial . Strategies of radioiodine ablation in patients with low‐risk thyroid cancer. N Engl J Med 2012; 366: 1663–1673. PubMed

Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel‐Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A. Ablation with low‐dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med 2012; 366: 1674–1685. PubMed

Wyatt G, Pugh SL, Wong RK, Sagar S, Singh AK, Koyfman SA, Nguyen‐Tân PF, Yom SS, Cardinale FS, Sultanem K, Hodson I, Krempl GA, Lukaszczyk B, Yeh AM, Berk L. Xerostomia health‐related quality of life: NRG oncology RTOG 0537. Qual Life Res 2016; 25: 2323–2333. PubMed PMC

Nakada K, Ishibashi T, Takei T, Hirata K, Shinohara K, Katoh S, Zhao S, Tamaki N, Noguchi Y, Noguchi S. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med 2005; 46: 261–266. PubMed

Jentzen W, Balschuweit D, Schmitz J, Freudenberg L, Eising E, Hilbel T, Bockisch A, Stahl A. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging. Eur J Nucl Med Mol Imaging 2010; 37: 2298–2306. PubMed

Jentzen W, Richter M, Nagarajah J, Poeppel TD, Brandau W, Dawes C, Bockisch A, Binse I. Chewing‐gum stimulation did not reduce the absorbed dose to salivary glands during radioiodine treatment of thyroid cancer as inferred from pre‐therapy (124)I PET/CT imaging. EJNMMI Physics 2014; 1: 100. PubMed PMC

Vissink A, Mitchell JB, Baum BJ, Limesand KH, Jensen SB, Fox PC, Elting LS, Langendijk JA, Coppes RP, Reyland ME. Clinical management of salivary gland hypofunction and xerostomia in head‐and‐neck cancer patients: successes and barriers. Int J Radiat Oncol Biol Phys 2010; 78: 983–991. PubMed PMC

Hoffman KE, Pugh SL, James JL, Scarantino C, Movsas B, Valicenti RK, Fortin A, Pollock J, Kim H, Brachman DG, Berk LB, Bruner DW, Kachnic LA. The impact of concurrent granulocyte‐macrophage colony‐stimulating factor on quality of life in head and neck cancer patients: results of the randomized, placebo‐controlled Radiation Therapy Oncology Group 9901 trial. Qual Life Res 2014; 23: 1841–1858. PubMed PMC

Durso SC. Oral manifestations of disease In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL, eds. Harrison´s principles of internal medicine. New York, NY: Mc Graw‐Hill, 2005; 194–201.

Ship JA, Fox PC, Baum BJ. How much saliva is enough? 'Normal' function defined. J Am Dent Assoc 1991; 122: 63–69. PubMed

Dugonjić S, Stefanović D, Ethurović B, Spasić‐Jokić V, Ajdinović B. Evaluation of diagnostic parameters from parotid and submandibular dynamic salivary glands scintigraphy and unstimulated sialometry in Sjögren's syndrome. Hell J Nucl Med 2014; 17: 116–122. PubMed

Burlison JS, Hartshorne MF, Voda AM, Cocks FH, Fair JR. SPECT/CT localization of oral radioiodine activity: a retrospective study and in‐vitro assessment. Nucl Med Commun 2013; 34: 1216–1222. PubMed PMC

Deshpande TS, Blanchard P, Wang L, Foote RL, Zhang X, Frank SJ. Radiation‐related alterations of taste function in patients with head and neck cancer: a systematic review. Curr Treat Options Oncol 2018; 19: 72. PubMed PMC

Dietlein M, Drzezga A. Taste dysfunction (dysgeusia) and radioiodine therapy of thyroid cancer – be aware of side effects by antidepressants and sedatives. Nuklearmedizin 2017; 56: 125–131. PubMed

Selvakumar T, Nies M, Klein Hesselink MS, Brouwers AH, van der Horst‐Schrivers ANA, Klein Hesselink EN, Tissing WJE, Vissink A, Links TP, Bocca G, Burgerhof JGM, van Dam EWCM, Havekes B, van den Heuvel‐Eibrink MM, Corssmit EPM, Kremer LCM, Netea‐Maier RT, van der Pal HJH, Peeters RP, Smit JWA, Plukker JTM, Ronckers CM, van Santen HM. Long‐term effects of radioiodine treatment on salivary gland function in adult survivors of pediatric differentiated thyroid carcinoma. J Nucl Med. 2019; 60: 172–177. PubMed

Verburg FA, Mäder U, Reiners C, Hänscheid H. Long‐term survival in differentiated thyroid cancer is worse after low‐activity initial post‐surgical 131I therapy in both high‐ and low‐risk patients. J Clin Endocrinol Metab 2014; 99: 4487–4496. PubMed

Kukulska A, Krajewska J, Gawkowska‐Suwińska M, Puch Z, Paliczka‐Cieslik E, Roskosz J, Handkiewicz‐Junak D, Jarzab M, Gubała E, Jarzab B. Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long‐term outcomes of treatment with 30, 60 and 100 mCi. Thyroid Res 2010; 3: 9. PubMed PMC